EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 12-Like

Ensembl ID : ENSSTUG00000047698
Gene Symbol: LOC115168347
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSSTUG00000023264
Gene Symbol: MAP3K13
2 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5-Like

Ensembl ID : ENSSTUG00000034153
Gene Symbol: LOC115193987
3 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5-Like

Ensembl ID : ENSSTUG00000032565
Gene Symbol: LOC115174881
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSSTUG00000001322
Gene Symbol: MAP3K8
3 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSSTUG00000016509
Gene Symbol: MAP3K8
3 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSSTUG00000027543
Gene Symbol: MAP3K9
3 Cross references
195 Possible Orthologues:

Monoglyceride Lipase-Like

Ensembl ID : ENSSTUG00000035047
Gene Symbol: LOC115166239
3 Cross references
202 Possible Orthologues:

Monoglyceride Lipase-Like

Ensembl ID : ENSSTUG00000039636
Gene Symbol: LOC115168305
3 Cross references
202 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSSTUG00000004617
Gene Symbol: MLNR
3 Cross references
174 Possible Orthologues:

Mu-Type Opioid Receptor-Like

Ensembl ID : ENSSTUG00000038656
Gene Symbol: LOC115152847
3 Cross references
208 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSSTUG00000047514
Gene Symbol: LOC115152155
2 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).